MEMBER
Alex Zhavoronkov, Ph.D.

MEMBER TYPE
Think Tank

FOCUS
Artificial Intelligence Technologies, Drug Discovery, and Biomarker Development

WORK
Founder & CEO of Insilico Medicine

Company

CONTACT

Your Name

Your full membership name

First Name

Last Name

Email address associated with your membership

Think Tank Member's Name

Think tank member you'd like to contact

Message

Briefly detail the purpose of your referral request

**CogWorld think tank members include some of today’s greatest minds in AI and future proofing.**
**Code 7893**

SUMMARY
Alex Zhavoronkov, Ph.D., is the founder and CEO of Insilico Medicine, a leader in next-generation artificial intelligence technologies for drug discovery and biomarker development. He is also the founder of Deep Longevity, Inc, a spin-off of Insilico Medicine developing a broad range of artificial intelligence-based biomarkers of aging and longevity servicing healthcare providers and the life insurance industry. In 2020 Deep Longevity was acquired by Endurance Longevity (HK: 0575).

Since 2015, he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and the generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for the prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling.

Under his leadership, Insilico raised over $300 million in multiple rounds from expert investors, opened R&D centers in six countries or regions, partnered with multiple pharmaceutical, biotechnology, and academic institutions, nominated 7 preclinical candidates, and entered human clinical trials with AI-discovered novel target and AI-designed novel molecule.

Prior to founding Insilico, he worked in senior roles at ATI Technologies (GPU company acquired by AMD in 2006), NeuroGNeuroinformatics, and Biogerontology Research Foundation. Since 2012 he published over 150 peer-reviewed research papers, and 2 books including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy" (Macmillan, 2013). He serves on the advisory or editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, Frontiers in Genetics, and founded and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (9th annual in 2022), the world's largest event on aging in the pharmaceutical industry.

He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

THINK TANK EDITORIAL

MEMBERAlex Zhavoronkov, Ph.D.

MEMBER
Alex Zhavoronkov, Ph.D.